EMACO for treatment of gestational trophoblastic neoplasia: A multinational multicenter study.

[1]  R. Berkowitz,et al.  Diagnosis and management of gestational trophoblastic disease: 2021 update , 2021, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[2]  R. Berkowitz,et al.  Treatment of high-risk gestational trophoblastic neoplasia and chemoresistance/relapsed disease. , 2021, Best practice & research. Clinical obstetrics & gynaecology.

[3]  R. Berkowitz,et al.  Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study. , 2020, Gynecologic oncology.

[4]  T. Lawrie,et al.  First-line chemotherapy in low-risk gestational trophoblastic neoplasia. , 2016, The Cochrane database of systematic reviews.

[5]  Athithan Rattanaburi,et al.  Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[6]  Jing Zhang,et al.  Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. , 2013, The Cochrane database of systematic reviews.

[7]  F. Sweep,et al.  Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  M. Cagayan.  High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy. , 2012, The Journal of reproductive medicine.

[9]  H. Shojaei,et al.  Comparison of pulsed actinomycin D versus 5‐day methotrexate for the treatment of low‐risk gestational trophoblastic disease , 2012, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[10]  D. Provencher,et al.  Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Lurain.  Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. , 2010, American journal of obstetrics and gynecology.

[12]  J. Schink,et al.  Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score > or = 7. , 2010, The Journal of reproductive medicine.

[13]  S. Wilailak,et al.  Actinomycin D Versus Methotrexate-Folinic Acid as the Treatment of Stage I, Low-Risk Gestational Trophoblastic Neoplasia: A Randomized Controlled Trial , 2009, International Journal of Gynecologic Cancer.

[14]  A. Sharifi,et al.  Pulse methotrexate versus pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia , 2008, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[15]  X. Xie,et al.  EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients , 2007, International Journal of Gynecologic Cancer.

[16]  J. Schink,et al.  Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. , 2006, The Journal of reproductive medicine.

[17]  G. Tulunay,et al.  Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia , 2005, International Journal of Gynecologic Cancer.

[18]  P. Hanjani,et al.  Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low‐risk gestational trophoblastic neoplasia , 2005, The Australian & New Zealand journal of obstetrics & gynaecology.

[19]  D. Fishman,et al.  Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. , 2003, Gynecologic oncology.

[20]  E. Kohorn.  The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: Description and critical assessment , 2000, International Journal of Gynecologic Cancer.

[21]  S. Kim,et al.  Effects of multiagent chemotherapy and independent risk factors in the treatment of high‐risk GTT —25 years experiences of KRI‐TRD , 1998, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[22]  E S Newlands,et al.  EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Friedlander,et al.  EMACO in High Risk Gestational Trophoblast Disease ‐ The Australian Experience , 1994, The Australian & New Zealand journal of obstetrics & gynaecology.

[24]  A. Berchuck,et al.  Alternating weekly chemotherapy with etoposide‐methotrexatedactinomycin/cyclophosphamide‐vincristine for high‐risk gestational trophoblastic disease , 1994, Obstetrics and gynecology.

[25]  A. Rademaker,et al.  Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high‐risk gestational trophoblastic disease , 1992, Obstetrics and gynecology.

[26]  E. Newlands,et al.  Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989 , 1991, British journal of obstetrics and gynaecology.

[27]  F. Landoni,et al.  EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). , 1988, Gynecologic oncology.

[28]  E. Newlands,et al.  Developments in chemotherapy for medium‐ and high‐risk patients with gestational trophoblastic tumours (1979–1984) , 1986, British journal of obstetrics and gynaecology.

[29]  G. Ross,et al.  SEQUENTIAL USE OF METHOTREXATE AND ACTINOMYCIN D IN THE TREATMENT OF METASTATIC CHORIOCARCINOMA AND RELATED TROPHOBLASTIC DISEASES IN WOMEN. , 1965, American journal of obstetrics and gynecology.